Ulinastatin alone does not reduce caspase 3-mediated apoptosis in protease-positive Aeromonas hydrophilia-induced sepsis

Journal of the Formosan Medical Association

Volumn 106, Issue 2, 2007, Pages 97-104

  Su, Bai Horng ^a   Chiu, Hsiao Yu ^a   Soga, Taketomo ^b   Lin, Kuo Juei ^a   Hsu, Chao Tien ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

Author keywords

Aeromonas hydrophilia; Apoptosis; Caspase 3; Protease inhibitor ulinastatin; Sepsis

Indexed keywords

CASPASE 3; CD4 ANTIGEN; CD8 ANTIGEN; PHOSPHATE BUFFERED SALINE; PROTEINASE; ULINASTATIN;

AEROMONAS HYDROPHILA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; GRAM NEGATIVE SEPSIS; IMMUNOFLUORESCENCE TEST; LYMPHOCYTE COUNT; MALE; MORTALITY; MOUSE; NONHUMAN; SURVIVAL RATE; THYMOCYTE;

EID: 33847770060     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60224-2     Document Type: Article

References (50)

1. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-71.
2. Manns BJ, Lee H, Doig CJ, et al. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002;347:993-1000.
3. Knaus WA, Harrell FE, Lynn J, et al. The SUPPORT Prognostic Model: objective estimates of survival for seriously ill hospitalized adults. Ann Intern Med 1995;122: 191-203.
4. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002;34:1084-93.
5. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997;25:1095-100.
6. Quartin AA, Schein RM, Kett DH, et al. Magnitude and duration of the effect of sepsis on survival: Department of Veteran's Affairs Systemic Sepsis Cooperative Studies Group. JAMA 1997;277:1058-63.
7. Edbrooke DL, Hibbert CL, Kingsley JM, et al. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 1999; 27:1760-7.
8. Opal SM. Concept of PIRO as a new conceptual framework to understand sepsis. Pediatric Crit Care Med 2005; 6:55-60.
9. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003;29:530-8.
10. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.
11. Glueck T, Opal SM. Advances in sepsis therapy. Drugs 2004; 64:837-59.
12. Dahmer MK, Randolph A, Vitali S, Quasney MW. Genetic polymorphisms in sepsis. Pediatric Crit Care Med 2005;6: 55-60.
13. Cook CH, Zhang Y, McGuinness BJ, et al. Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Infect Dis 2002;185: 1395-400.
14. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001;163:316-21.
15. Reddy RC, Chen GH, Tekchandani PK, et al. Sepsis-induced immunosuppression: from bad to worse. Immunol Res 2001;24:273-87.
16. Ayala A, Song GY, Chung CS, et al. Immune depression in polymicrobial sepsis: the role of necrotic (injured) tissue and endotoxin. Crit Care Med 2000;28:2949-55.
17. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002;30:58-63.
18. Weighardt H, Heidecke CD, Emmanuilidis K, et al. Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production. Surgery 2000;127:309-15.
19. Ayala A, O'Neill PJ, Uebele SA, et al. Mechanism of splenic immunosuppression during sepsis: key role of Kupffer cell mediators. J Trauma 1997;42:882-8.
20. Carcillo JA. Pediatric septic shock and multiple organ failure. Critical Care Clinics 2003;19:413-40.
21. Weaver JG, Rouse MS, Steckelberg JM, Badley AD. Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. FASEB J 2004;18: 1185-91.
22. Hemmer CJ, Lehr HA, Westphal K, et al. Plasmodium falciparum malaria: reduction of endothelial cell apoptosis in vitro. Infect Immun 2005;73:1764-70.
23. Maegele M, Gregor S, Steinhausen E, et al. The long-distance tertiary air transfer and care of tsunami victims: injury pattern and microbiological and psychological aspects. Crit Care Med 2005;33:1136-40.
24. Janda JM, Abbott SL. Evolving concepts regarding the genus Aeromonas: an expanding panorama of sepsis, disease presentations, and unanswered questions. Clin Infect Dis 1998;27:332-44.
25. Chacon MR, Figueras MJ, Castro-Escarpulli G, et al. Distribution of virulence genes in clinical and environmental isolates of Aeromonas spp. Antonie Van Leeuwenhoek 2003;84:269-78.
26. Lau SM, Peng MY, Chang FY. Outcomes of Aeromonas bacteremia in patients with different types of underlying disease. J Microbiol Immunol Infect 2000;33:241-7.
27. Ko WC, Chuang YC. Aeromonas bacteremia: review of 59 episodes. Clin Infect Dis 1995;20:1298-304.
28. Lin YS, Lei HY, Low TLK, et al. In vivo induction of apoptosis in immature thymocytes by staphylococcal enterotoxin. Br J Immunol 1992;149:1156-60.
29. Hotchkiss RS, Swanson PF, Kundson CM, et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 1999;162:4148-56.
30. Wang SD, Huang KJ, Lin YS, Lei HY. Sepsis-induced apoptosis of the thymocytes in mice. J Immunol 1994;152:5014-21.
31. Forket PG. In vivo formation and localization of 1,1-dichloroethylene epoxide in murine liver: identification of its glutathione conjugate 2-s-glutathionyl acetate. J Phamacol Exp Ther 1999;290:1299-306.
32. Forket PG, Martin EJ. Evidence that 1,1-dichloroethylene induces apoptotic cell death in murine liver. J Phamacol Exp Ther 2004;310:33-42.
33. Chacón MR, Castro-Escarpullar G, Solar L, et al. A DNA probe specific for Aeromonas colonies. Diagn Microbiol Infect 2002;44:221-5.
34. Aydin A, Nazik H, Kuvat SV, et al. External decontamination of wild leeches with hypochloric acid. BMC Infect Dis 2004;4:28.
35. Vadivelu J, Puthucheary SD, Navaratnam P. Exotoxin profiles of clinical isolates of Aeromonas hydrophilia. J Mec Microbiol 1991;34:363-7.
36. Joanne MR, Houston CW, Kurosky A. Bioactivity and immunological characterization of a cholera toxin-cross-reactive cytolytic enterotoxin from Aeromonas hydrophilia. Infect Immun 1989;57:1170-9.
37. Leung KY, Stevenson MW. Tn-5-induced protease-deficient strains of Aeromonas hydrophilia with reduced virulence for fish. Infect Immun 1988;56:2639-44.
38. Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002;166:1475-82.
39. Ayala A, Ertel W, Chaudry IH. Trauma-induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes. Shock 1996:5:79-90.
40. + lymphocyte subsets and its relationship with the phenotype of responding T-cells. Cytometry 1999; 38:95-101.
41. Volk HD, Reinke P, Krausch D, et al. Monocyte deactivation - rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996;22:S474-81.
42. Bauer J, Reich Z. Uber die antitryptiche Wirkung des Harns. Med Klin 1909;46:1744-52.
43. Tsujino T, Komatsu Y, Isayama H, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005;3:376-83.
44. Tani T, Aoki H, Yoshoka T, et al. Treatment of septic shock with a protease inhibitor in a canine model: a prospective, randomized, controlled trial. Crit Care Med 1993;21: 925-30.
45. Endo S, Inoue Y, Yamada A, et al. Ulinastatin inhibits the production of cytokine. Jpn J Acute Med 1990;14:341-2.
46. Shibutani Y, Kunihiro Y. Preventive effects of ulinastatin on tissue degradation. Jpn Pharmacol Ther 1986;14: 6057-72.
47. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6.
48. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
49. Enari M, Sakahira H, Yokoyama H, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998;391:43-50.
50. Nakatani K, Takeshita S, Tsujimoto H, et al. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 2001;69:241-7.